Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Mylan Stories

2014-01-02 12:23:05

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the J.P. Morgan 32(nd) Annual Healthcare Conference on Tuesday Jan. 14, 2014, in San Francisco. The presentation is scheduled to begin at 7:30 p.m. ET on Tuesday Jan. 14, 2014. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web...

2014-01-02 12:22:33

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that CEO Heather Bresch will present at the Goldman Sachs Healthcare CEOs Unscripted: A View From the Top Conference on Tuesday Jan. 7, 2014, in Boston. The presentation is scheduled to begin at 8:45 a.m. ET on Tuesday Jan. 7, 2014. Interested parties can access a live webcast of the presentation via the investor relations...

2014-01-02 12:22:28

PITTSBURGH, Jan. 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that Rakesh Bamzai has joined the company and has been appointed president, India Commercial and Emerging Markets. Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, where he played a key role in building the company's global biopharmaceutical business. He had overall responsibility for active...

2013-12-18 12:25:21

PITTSBURGH, Dec. 18, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has received all regulatory approvals and has completed an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize a novel long-acting muscarinic antagonist (LAMA) compound for various indications. Mylan expects that this product, which is ready to enter Phase IIb, will be submitted to the U.S. Food and Drug Administration (FDA) for approval as a new...

2013-12-17 16:23:22

Agreement includes a no-later-than July 9, 2015 launch PITTSBURGH, Dec. 17, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. and partner, Banner Pharmacaps Inc. (a wholly-owned subsidiary of Patheon Inc.), have entered into a settlement and license agreement with Eisai Inc. and Valeant Pharmaceuticals Luxembourg S.a.r.l that will resolve patent litigation related to Bexarotene Capsules, 75 mg. Bexarotene is the generic...

2013-12-17 12:22:47

New Report from Decision Resources Explores Near-Term Opportunities in the U.S. Generic Drug Market BURLINGTON, Mass., Dec. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that between 2013 and 2020, 40 blockbuster brands will lose patent exclusivity in the United States. According to the new Strategic Insights report entitled Indian Generics Manufacturers Penetrate U.S. Generics...

2013-12-11 23:05:06

New Spanish-language Resource and Results from a National Survey to be Released Washington, DC (PRWEB) December 11, 2013 “Severe allergic reactions are serious, and they can be life-threatening if not treated immediately. Hispanics need to know what anaphylaxis is, how to prevent it, and above all, what to do if they or their children have an anaphylactic reaction. It can mean the difference between life and death,” said Dr. Jane L. Delgado, President and CEO of the National Alliance...

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....

2013-12-05 08:29:16

PITTSBURGH, Dec. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Cabergoline Tablets...

2013-12-04 16:25:54

Purchase Price Restructured to Hold Back $250 Million Contingent Upon Satisfaction of Certain Regulatory Conditions PITTSBURGH, Dec. 4, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has completed the acquisition of the Agila injectables businesses from Strides Arcolab Limited (BSE: 532531, NSE: STAR) for up to $1.75 billion, which includes $250 million in contingent consideration. Since the initial announcement of this acquisition, the final transaction...